Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 367Ovarian Neoplasms 99Lung Neoplasms 98Neoplasms 84Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 49Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Endometrial Neoplasms 30Carcinoma 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 24Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 12Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

atezolizumab 2Etoposide 2Carboplatin 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Cancer Extensive Stage × Carboplatin × Clear all
NCT07227597 2026-05-28

MK-6070-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
170 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡